Stock Report

All about this stock under one free report Last Updated: 09-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Ascendis Pharma A/S - ADR

Stock Card factsheet share-fund-plan-icon

$238.66

up-down-arrow $-7.48 (-3.04%)

As on 08-May-2026 16:00EDT

Market cap

info icon

$14,574 Mln

Revenue (TTM)

info icon

$718 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

78.1

Div. Yield

info icon

0 %

Ascendis Pharma A/S - ADR Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio
NASDAQ
NASDAQ

Stock Range

Today’s Range

Low: 236.22 High: 250.27

52 Week Range

Low: 150.89 High: 250.74

Liquidityliquidity Moderate

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -8.2 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -20.7

  • Debt to EquityDebt to Equity information

    -5.4

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-3.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    61,779,750

10 Years Aggregate

CFO

€-2,184.14 Mln

EBITDA

€-2,320.00 Mln

Net Profit

€-2,450.27 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Ascendis Pharma A/S - ADR
11.9 8.2 9.8 48.2 36.2 12.4 31.0
BSE Sensex
-8.7 3.6 -7.5 -4.2 8.2 9.5 11.9
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 08-May-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Ascendis Pharma A/S - ADR
54.9 9.2 3.1 -9.2 -19.3 19.9 122.1
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in (€ Mln)

Annual

*All values are in (€ Mln)

Annual

*All values are in (€ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Ascendis Pharma A/S - ADR
238.7 14,573.8 691.7 -219.0 -13.7 163.2 -- 78.1
Genenta Science SpA ADR (GNTA)
0.6 16.3 0.0 -6.3 -- -36.5 -- 0.6

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Ascendis Pharma A/S - ADR

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients...  with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900  Read more

  • President, CEO, Member of Executive Board & Executive Director

    Mr. Jan Moller Mikkelsen

  • President, CEO, Member of Executive Board & Executive Director

    Mr. Jan Moller Mikkelsen

  • Headquarters

    Hellerup

  • Website

    https://ascendispharma.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Ascendis Pharma A/S - ADR

The share price of Ascendis Pharma A/S - ADR is $238.66 (NASDAQ) as of 08-May-2026 16:00 EDT. Ascendis Pharma A/S - ADR has given a return of 36.2% in the last 3 years.

Since, TTM earnings of Ascendis Pharma A/S - ADR is negative, P/E ratio is not available.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
-59.76
-80.42
2024
-21.77
-77.86
2023
-14.81
-48.94
2022
-11.73
25.97
2021
-18.89
8.20

The 52-week high and low of Ascendis Pharma A/S - ADR are Rs 250.74 and Rs 150.89 as of 09-May-2026.

Ascendis Pharma A/S - ADR has a market capitalisation of $ 14,574 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Ascendis Pharma A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.